Genmab Valuation Multiples

Genmab Overview

About Genmab

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Founded

1998

HQ

Employees

2.8K

Website

genmab.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $4B

EBITDA: $1B

EV

$22B

Valuation Multiples

Multiples.vc

Start free trial

Genmab Financials

Genmab reported last 12-month revenue of $4B and EBITDA of $1B.

In the same LTM period, Genmab generated $4B in gross profit, $1B in EBITDA, and $913M in net income.

Genmab P&L

In the most recent fiscal year, Genmab reported revenue of $4B and EBITDA of $1B.

Genmab expects next 12-month revenue of XXX and NTM EBITDA of XXX

Genmab Stock Performance

Genmab has current market cap of $18B, and enterprise value of $22B.

Genmab's stock price is $29.39.

Genmab Valuation Multiples

Genmab trades at 5.6x EV/Revenue multiple, and 18.3x EV/EBITDA.

Genmab Financial Valuation Multiples

As of April 5, 2026, Genmab has market cap of $18B and EV of $22B.

Equity research analysts estimate Genmab's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Genmab has a P/E ratio of 19.8x.

Genmab Margins & Growth Rates

Genmab's revenue in the last 12 month grew by 17%.

Genmab's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.8M for the same period.

Genmab's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Genmab's rule of X is 71% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Genmab Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Genmab M&A Activity

Genmab acquired XXX companies to date.

Last acquisition by Genmab was on XXXXXXXX, XXXXX. Genmab acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Genmab Investment Activity

Genmab invested in XXX companies to date.

Genmab made its latest investment on XXXXXXXX, XXXXX. Genmab invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).